Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?

• Authors: Jacopo Giuliani , Marina Marzola
• Languages of publication: EN

Abstracts

EN

Keywords

EN

Cetuximab; Head and neck cancer; Cisplatin; Concomitant radiotherapy

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 9
• Issue: 2
• Pages: 279-284

Dates

published

1 - 4 - 2014

online

13 - 2 - 2014

Contributors

author

Jacopo Giuliani

• Palliative Care Unit, Mater Salutis Hospital, ULSS 21, Legnago Verona, Italy

author

Marina Marzola

• Clinical Oncology Unit — St. Anna University-Hospital, Ferrara, Italy

References

• [1] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300 http://dx.doi.org/10.3322/caac.20073[Crossref]
• [2] Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944 http://dx.doi.org/10.1056/NEJMoa032646[Crossref]
• [3] Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist. 2005;10:215–224 http://dx.doi.org/10.1634/theoncologist.10-3-215[Crossref]
• [4] Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098 http://dx.doi.org/10.1056/NEJMoa031317[Crossref]
• [5] Licitra L, Felip E; ESMO Guidelines Working Group. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:121–122 http://dx.doi.org/10.1093/annonc/mdp149[Crossref]
• [6] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–28 http://dx.doi.org/10.1016/S1470-2045(09)70311-0[Crossref]
• [7] Frampton JE. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs. 2010;70:1987–2010 http://dx.doi.org/10.2165/11205010-000000000-00000[Crossref]
• [8] Forastiere AA. Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol. 2008;97:701–707 http://dx.doi.org/10.1002/jso.21012[Crossref]
• [9] Pignon JP, le Maítre A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACHNC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14 http://dx.doi.org/10.1016/j.radonc.2009.04.014[Crossref]
• [10] Levy AR, Johnston KM, Sambrook J, et al. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Curr Med Res Opin 2011;27:2253–2259 http://dx.doi.org/10.1185/03007995.2011.633989[Crossref][WoS]
• [11] Vermorken JB, Mesia R, Rivera F, et al. Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–1127 http://dx.doi.org/10.1056/NEJMoa0802656[Crossref]
• [12] Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171–2177 http://dx.doi.org/10.1200/JCO.2006.06.7447[Crossref]
• [13] Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072–1078 http://dx.doi.org/10.1200/JCO.2004.00.1792[Crossref]
• [14] Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL, Gibson MK. The role of cetuximab in the management of head and neck cancers. Expert Opin Biol Ther 2012;12:517–528 http://dx.doi.org/10.1517/14712598.2012.667397[WoS][Crossref]

Identifiers

DOI

10.2478/s11536-013-0154-9